Published in final edited form as:

J Am Chem Soc. 2009 October 28; 131(42): 15096–15097. doi:10.1021/ja906432e.

A Click Chemistry Mediated *in vivo* Activity Probe for Dimethylarginine Dimethylaminohydrolase

Yun Wang[†], Shougang Hu^{†,‡}, and Walter Fast^{†,‡}

[†]Division of Medicinal Chemistry, College of Pharmacy, University of Texas, Austin, TX 78712

[‡]Texas Institute for Drug and Diagnostic Development; University of Texas, Austin, TX 78712

Asymmetric *N*^ω,*N*^ω-dimethyl-L-arginine (ADMA) is an endogenously produced inhibitor of human nitric oxide synthase and an emerging biomarker for endothelial dysfunction in cardiovascular disease.¹ Concentrations of ADMA are tightly controlled by two isoforms of its catabolic enzyme dimethylarginine dimethylaminohydrolase (DDAH-1 and DDAH-2) that have different tissue distributions.² Homozygous disruption of the *Ddah1* gene in mice results in embryonic lethality; heterozygous mice have elevated concentrations of plasma ADMA and display endothelial dysfunction.³ Accordingly, dysregulation of DDAH activity has been studied as a mediating factor for endothelial dysfunction in a number of disease states including hyperhomocysteinemia,⁴ renal failure⁵ and diabetes.⁶ However, the existing methodology has shortcomings. Measurements of transcript mRNAs and immunoblots by DDAH-selective antibodies have been used to monitor changes in DDAH expression, but these values do not always correlate well with the activity of DDAH because the enzyme can be inhibited by physiologically relevant modulators such as homocysteine,⁷ *S*-nitroso-L-homocysteine,^{8–10} zinc (II),¹¹ 4-hydroxy-2-nonenal,¹² nitric oxide^{13,14} and other reactive nitrogen and oxygen species. Likewise, enzyme activity assays are also problematic because they are performed after cell lysis and homogenization, which removes DDAH from its cellular environment and alters the concentrations of modulators. A cell permeable probe to detect enzyme activity would likely prove more relevant for the study of biological function. Therefore, to better understand the regulation of DDAH in normal and pathophysiology, we developed a two part click-chemistry mediated activity-based probe that labels active DDAH-1 in intact mammalian cells, but does not label an inactive mutant or inhibited enzyme.

In prior work, we discovered that 2-chloroacetamide (CAA) selectively modifies the active site Cys of DDAH.¹⁵ Subsequently, a similar 2-haloamide activity probe specific for a related enzyme, peptidylarginine deiminase-4, was demonstrated in *Escherichia coli* cell lysates.¹⁶ As a candidate DDAH probe for *in vivo* use with mammalian cell cultures, we synthesized *N*-but-3-ynyl-2-chloroacetamide (**1**; Supporting Information). The simple butynyl chain was appended to CAA to minimize its impact on selectivity and bioavailability yet still provide a handle for variable functionalization using a click reaction after cell lysis, here a Cu (I) catalyzed 1,3-dipolar cycloaddition¹⁷ with an azide labeled-biotin (Figure 1), a strategy proven successful with other enzyme superfamilies.¹⁸

By transient transfection, human DDAH-1 bearing an *N*-terminal Myc-tag was expressed in HEK 293T cells. Addition of **1** (150 μM) to the growth medium was followed by a short

WaltFast@mail.utexas.edu.

SUPPORTING INFORMATION AVAILABLE Twelve pages including the synthetic procedure for (**1**) and biotin-PEO₃-azide, the cloning procedure for myc-tagged human DDAH-1 and the conditions for biotinylation and Western blot analysis. This material is available free of charge via the Internet at <http://pubs.acs.org>.

incubation, cell washing and harvesting. Cells were subsequently lysed by multiple freeze/thaw cycles and the resulting lysate incubated with biotin-PEO₃-azide (Supporting Information) and catalysts for the cycloaddition reaction followed by SDS-PAGE to resolve the crude protein mixture. The presence of myc and biotin was demonstrated by Western blot using rabbit anti-myc and mouse anti-biotin primary antibodies, and two near-infrared dye labeled secondary antibodies with emissions at 680 nm (anti-rabbit, red) and 800 nm (anti-mouse, green) (Figure 2, Supporting Information) that were chosen for their linear concentration-dependent response.¹⁹ Response to the myc tag (red) indicated consistent levels of DDAH-1 expression and loading. Response to the biotin tag (green) was observed when cells were treated by **1**, but not when **1** was omitted. An inactive DDAH-1 in which the active-site Cys₂₇₄ is mutated to Ala is also not labeled by **1**, despite the presence of five other Cys residues in its primary sequence. Addition of CAA (25 μ M) prior to addition of **1** blocks biotinylation, indicating that CAA has sufficient bioavailability to react with DDAH-1 in 293T cells and that CAA and **1** compete for the same site. Mock transfection with an empty expression vector or 293T cells alone did not result in a labeled band at the expected position for DDAH-1. These experiments clearly demonstrate that **1** can label active DDAH-1 in cultured mammalian cells.

To determine whether **1** is capable of detecting reversible inhibition of DDAH-1 in cells, a challenge experiment²⁰ was performed using a competitive reversible inhibitor of DDAH-1, *N*⁵-(1-iminopropyl)-L-ornithine (**4**) (K_i = 50 μ M), that we previously developed as a non-hydrolyzable analog of the substrate *N*^ω-methyl-L-arginine.²¹ Cells were preincubated with varying concentrations of **4**, followed by addition of **1**, washing, harvesting and lysis. For dose dependent studies, response to the biotin tag was normalized for expression levels of myc-DDAH-1. In the absence of inhibitor, DDAH-1 was effectively biotinylated, indicating that the active site Cys₂₇₄ was available to react with **1** (Figure 3).

Biotinylation of DDAH-1 diminished with increasing concentrations of **4**, indicating both the bioavailability of **4** and its competition with **1** for binding to the active site of DDAH-1, resulting in a level of inhibition that defines an *in vivo* IC₅₀ value of 350 $\pm$ 90 μ M. The *in vivo* IC₅₀ is approximately 7-fold higher than the *in vitro* K_i value, with the difference in potency representing a combination of factors including bioavailability, protein binding, competition with endogenous DDAH-1 modulators and other variables not easily mimicked during *in vitro* tests.

In conclusion, the data presented herein demonstrate that **1** serves as a novel click chemistry mediated *in vivo* activity probe that labels the active fraction of DDAH-1 in intact mammalian cells and that can be blocked by the presence of competitive reversible and irreversible inhibitors. Incorporation of the alkyne tag allows the flexibility to derivatize with a variety of reagents after *in vivo* tagging.²² The two color imaging system enables normalization to account for variable protein expression when determining *in vivo* IC₅₀ values of inhibitors. Additionally, the small size and simplicity of **1** suggest its use as a broad-specificity probe for labeling endogenous DDAH isoforms and enzymes with similar pharmacophores, the subject of ongoing studies. This probe provides a novel tool for the analysis of DDAH-1 activity in normal and pathophysiological states relevant to cardiovascular disorders and should allow more meaningful studies of the etiology of endothelial dysfunction.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health (GM69754), the Robert A. Welch Foundation (F-1572) and a seed grant from the Texas Institute for Drug and Diagnostic Development (Welch Foundation Grant # H-F-0032).

REFERENCES

1. Boger RH, Maas R, Schulze F, Schwedhelm E. *Pharmacol Res.* 2009[Epub ahead of print; doi:10.1016/j.phrs.2009.07.001]
2. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. *Biochem J* 1999;343(Pt 1):209–14. [PubMed: 10493931]
3. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. *Nat Med* 2007;13:198–203. [PubMed: 17273169]
4. Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, Cooke JP, Faraci FM, Lentz SR. *Am J Physiol Heart Circ Physiol* 2008;295:H816–25. [PubMed: 18567702]
5. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S. *J Am Soc Nephrol* 2006;17:2176–83. [PubMed: 16807406]
6. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. *Diabetes* 2008;57:172–80. [PubMed: 17909098]
7. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. *Circulation* 2001;104:2569–75. [PubMed: 11714652]
8. Knipp M, Braun O, Vasak M. *J Am Chem Soc* 2005;127:2372–3. [PubMed: 15724974]
9. Hong L, Fast W. *J. Biol. Chem* 2007;282:34684–34692. [PubMed: 17895252]
10. Braun O, Knipp M, Chesnov S, Vasak M. *Protein Sci* 2007;16:1522–34. [PubMed: 17600152]
11. Knipp M, Charnock JM, Garner CD, Vasak M. *J Biol Chem* 2001;276:40449–56. [PubMed: 11546769]
12. Forbes SP, Druhan LJ, Guzman JE, Parinandi N, Zhang L, Green-Church KB, Cardounel AJ. *Biochemistry* 2008;47:1819–26. [PubMed: 18171027]
13. Knipp M, Braun O, Gehrig PM, Sack R, Vasak M. *J Biol Chem* 2003;278:3410–6. [PubMed: 12441345]
14. Leiper J, Murray-Rust J, McDonald N, Vallance P. *Proc Natl Acad Sci U S A* 2002;99:13527–32. [PubMed: 12370443]
15. Stone EM, Schaller TH, Bianchi H, Person MD, Fast W. *Biochemistry* 2005;44:13744–52. [PubMed: 16229464]
16. Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. *J Am Chem Soc* 2006;128:1092–3. [PubMed: 16433522]
17. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem Int Ed Engl* 2002;41:2596–9. [PubMed: 12203546]
18. Speers AE, Adam GC, Cravatt BF. *J Am Chem Soc* 2003;125:4686–7. [PubMed: 12696868]
19. Weldon S, Ambroz K, Schutz-Geschwender A, Olive DM. *Anal Biochem* 2008;375:156–8. [PubMed: 18162169]
20. Leung D, Hardouin C, Boger DL, Cravatt BF. *Nat Biotechnol* 2003;21:687–91. [PubMed: 12740587]
21. Wang Y, Monzingo AF, Hu S, Schaller TH, Robertus JD, Fast W. *Biochemistry* 2009;48:8624–35. [PubMed: 19663506]
22. Sadaghiani AM, Verhelst SH, Bogyo M. *Curr Opin Chem Biol* 2007;11:20–8. [PubMed: 17174138]

Figure 1.

In vivo activity probe for DDAH-1. HEK 293T cells expressing myc-tagged DDAH-1 are treated with **1**, washed, lysed and reacted with biotin-PEO₃-azide and catalysts to biotinylate the active fraction of DDAH-1. The *syn/anti* ratio of **3** has not been determined.

Figure 2.

Two-color imaging for DDAH-1 activity. (A) Red and green coloring correspond to anti-myc and anti-biotin Western blot signals, respectively. (B) Coomassie staining of the same samples used for (A). The MW_{calcd} of myc-DDAH-1 is 35,894 Da.

Figure 3.

In vivo inhibition assay. Normalized fluorescence intensities for the biotin-derived signal are fit with an *in vivo* IC_{50} of $350 \pm 90 \mu\text{M}$. (Inset) Two-color Western blots reflect presence of myc (red) and biotin (green) tags after labeling of intact HEK 293T cells in the presence of 0, 10, 20, 40, 80, 160, 320, 640 and 1,280 μM **4** (left to right).